New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
NCT ID NCT07417241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cancer growth. Participants will be randomly assigned to one of the two treatments and monitored for side effects and progression-free survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?